We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Using Transcriptome Analysis to Detect Asymptomatic Alzheimer’s Disease

By LabMedica International staff writers
Posted on 29 Jul 2019
Print article
Image: In brains affected by Alzheimer’s disease, abnormal levels of the beta-amyloid protein clump together to form plaques (seen in brown) that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles (seen in blue) within neurons, harming synaptic communication between nerve cells (Photo courtesy of the [U.S.] National Institute on Aging).
Image: In brains affected by Alzheimer’s disease, abnormal levels of the beta-amyloid protein clump together to form plaques (seen in brown) that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles (seen in blue) within neurons, harming synaptic communication between nerve cells (Photo courtesy of the [U.S.] National Institute on Aging).
Transcriptome analysis was used as a method for detecting individuals with Alzheimer’s disease (AD) who were not yet displaying symptoms of the disorder.

Currently there are no good methods for detecting asymptomatic AD patients despite the fact that they may share similar neuropathological burdens as symptomatic individuals while experiencing significantly different rates of cognitive decline.

To develop a method for diagnosing asymptomatic AD patients, investigators at the University of California, San Diego (USA) used the transcriptome as a proxy for functional state, and selected 414 expression profiles of symptomatic AD subjects and age-matched non-demented controls from a community-based neuropathological study. Because it includes all mRNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time. Unlike the genome, which is roughly fixed for a given cell line (excluding mutations), the transcriptome can vary with external environmental conditions.

Results of the transcriptome survey revealed that by combining brain tissue-specific protein interactomes (an interactome is the whole set of molecular interactions in a particular cell) with gene networks, the investigators were able to identify functionally distinct composite clusters of genes that revealed extensive changes in expression levels in AD. Global expression for clusters broadly corresponding to synaptic transmission, metabolism, cell cycle, survival, and immune response were downregulated, while the upregulated cluster included largely uncharacterized processes.

These results highlighted the utility of integrating protein interactions with gene perturbations to generate a comprehensive framework for characterizing alterations in the molecular network as applied to AD.

“One of the big problems in AD research is identifying patients at risk at the right time,” said senior author Dr. Robert Rissman, professor of neurosciences at the University of California, San Diego. “Understanding the gene networks that may change in specific patient groups can help streamline clinical trials recruitment efforts and reduce costs and time to enroll trials. With the field shifting more and more toward pre-symptomatic disease, we need to expand our understanding of the molecular mechanisms that underlie the entire disease spectrum.”

The transcriptome analysis study was published in the July 23, 2019, issue of the journal Cell Reports.

Related Links:
University of California, San Diego

New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
Gold Supplier
COVID-19 Test
ID NOW COVID-19
New
Molecular Diagnostics Integrated System
SENTiNAT 200
New
COVID-19 ELISA Test
Kantaro COVID-SeroKlir

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis (Photo courtesy of Dr. Christopher Wiley)

Novel Lipid Biomarker Detects Senescent Cells

A recent paper identified a lipid biomarker indicative of cellular senescence and described a method to evaluate its effect on the molecular events that lead to senescence. Cellular senescence is a... Read more

Industry

view channel
Image: The Luminex Aries® System (Photo courtesy of Luminex Corporation)

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

DiaSorin S.p.A. (‎Saluggia‎, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.